TGTX

TG Therapeutics, Inc. Press Releases

$8.44
*  
0.48
5.38%
Get TGTX Alerts
*Delayed - data as of Jul. 25, 2014  -  Find a broker to begin trading TGTX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    TGTX Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

TG Therapeutics' Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas
7/21/2014 4:05:00 PM - GlobeNewswire

TG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Business Update
7/21/2014 4:05:00 PM - GlobeNewswire

TG Therapeutics Completes Global Licensing Agreement With Ligand Pharmaceuticals for the Development of Inhibitors of IRAK4
6/24/2014 8:08:00 AM - GlobeNewswire

Ligand Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program
6/24/2014 3:01:00 AM - Business Wire

TG Therapeutics, Inc. to Present at the 2014 JMP Securities Healthcare Conference
6/23/2014 8:30:00 AM - GlobeNewswire

TG Therapeutics, Inc. to Present at the 2014 Wells Fargo Healthcare Conference
6/16/2014 4:30:00 PM - GlobeNewswire

TG Therapeutics' TG-1101 (Ublituximab) in Combination With Ibrutinib Demonstrates Compelling Clinical Activity and Safety Profile in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
6/13/2014 5:30:00 AM - GlobeNewswire

TG Therapeutics, Inc. Announces Presentation of Single Agent Data for Both TG-1101 and TGR-1202 in Ongoing Phase I Clinical Studies
5/30/2014 1:55:00 PM - GlobeNewswire

TG Therapeutics, Inc. Announces Clinical Data Presentations for TG-1101 and TGR-1202 at the European Hematology Association (EHA) Meeting in Milan, Italy
5/22/2014 4:36:00 PM - GlobeNewswire

TG Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Business Update
5/12/2014 4:30:00 PM - GlobeNewswire

Coronado Biosciences Announces February Inducement Award
5/9/2014 4:05:00 PM - GlobeNewswire

TG Therapeutics, Inc. to Host Conference Call on First Quarter 2014 Financial Results and Business Update
5/9/2014 8:30:00 AM - GlobeNewswire

TG Therapeutics, Inc. Provides Update on a Modified TGR-1202 Formulation and Fed-State Dosing With Data Demonstrating Significantly Higher TGR-1202 Exposure
5/8/2014 8:30:00 AM - GlobeNewswire

TG Therapeutics, Inc. Announces Clinical Data Presentations at Upcoming Conferences
5/6/2014 8:30:00 AM - GlobeNewswire

TG Therapeutics, Inc. to Present at the 39th Annual Deutsche Bank Healthcare Conference
5/5/2014 8:30:00 AM - GlobeNewswire